abiraterone,olaparib
astrazeneca,merck
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
noel clarke discussing rationale for ar inhibition and parp inhibitor and os results from propel. data overwhelming for hrr mutated patients, not quite so for non hrr group. let the debate begin! #gu23 
GU Oncologist/Researcher @UCSD interested in #CtDNA #MRD #BladderCancer. Views are my own.